Humacyte, Inc. Increase (Decrease) in Accrued Liabilities
Humacyte, Inc. (HUMA) reported Increase (Decrease) in Accrued Liabilities of -$1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilities · last filed 2026-08-12
- Humacyte, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-06-30 was $688.00K.
- Humacyte, Inc. increase (decrease) in accrued liabilities for the quarter ending 2026-03-31 was -$2.18M.
- Humacyte, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-12-31 was -$263.00K, a 201.94% decline year-over-year.
- Humacyte, Inc. increase (decrease) in accrued liabilities for the quarter ending 2025-09-30 was $957.00K, a 56.52% decline year-over-year.
- Humacyte, Inc. increase (decrease) in accrued liabilities for fiscal 2025 was -$1.71M, a 176.36% decline from fiscal 2024.
- Humacyte, Inc. increase (decrease) in accrued liabilities for fiscal 2024 was $2.24M, a 3.28% increase from fiscal 2023.
- Humacyte, Inc. increase (decrease) in accrued liabilities for fiscal 2023 was $2.17M, a 777.33% increase from fiscal 2022.
- Humacyte, Inc. increase (decrease) in accrued liabilities for fiscal 2022 was $247.00K, a 87.86% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities 3 month | Increase (Decrease) in Accrued Liabilities 6 month | Increase (Decrease) in Accrued Liabilities 9 month | Increase (Decrease) in Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $688.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$1.50M 10-Q · filed 2026-08-12 | -$1.76M derived: sum of 3 quarters · filed 2026-08-12 | -$802.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | -$2.18M 10-Q · filed 2026-05-13 | -$2.45M derived: sum of 2 quarters · filed 2026-05-13 | -$1.49M derived: sum of 3 quarters · filed 2026-05-13 | -$1.63M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | -$263.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $694.00K derived: sum of 2 quarters · filed 2026-03-27 | $558.00K derived: sum of 3 quarters · filed 2026-08-12 | -$1.71M 10-K · filed 2026-03-27 |
| 2025-09-30 | $957.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $821.00K derived: sum of 2 quarters · filed 2026-08-12 | -$1.45M 10-Q · filed 2025-11-12 | -$1.19M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | -$136.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$2.40M 10-Q · filed 2026-08-12 | -$2.15M derived: sum of 3 quarters · filed 2026-08-12 | $56.00K derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | -$2.27M 10-Q · filed 2026-05-13 | -$2.01M derived: sum of 2 quarters · filed 2026-05-13 | $192.00K derived: sum of 3 quarters · filed 2026-05-13 | $2.08M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $258.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $2.46M derived: sum of 2 quarters · filed 2026-03-27 | $4.34M derived: sum of 3 quarters · filed 2026-03-27 | $2.24M 10-K · filed 2026-03-27 |
| 2024-09-30 | $2.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $4.09M derived: sum of 2 quarters · filed 2025-11-12 | $1.98M 10-Q · filed 2025-11-12 | $1.57M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | $1.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$221.00K 10-Q · filed 2025-08-11 | -$631.00K derived: sum of 3 quarters · filed 2025-08-11 | $2.67M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$2.11M 10-Q · filed 2025-05-13 | -$2.52M derived: sum of 2 quarters · filed 2025-05-13 | $784.00K derived: sum of 3 quarters · filed 2025-05-13 | $657.00K derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$410.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.89M derived: sum of 2 quarters · filed 2025-03-31 | $2.76M derived: sum of 3 quarters · filed 2025-03-31 | $2.17M 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $3.17M derived: sum of 2 quarters · filed 2024-11-08 | $2.58M 10-Q · filed 2024-11-08 | $1.62M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | -$127.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$724.00K 10-Q · filed 2024-08-13 | -$1.68M derived: sum of 3 quarters · filed 2024-08-13 | $94.00K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$597.00K 10-Q · filed 2024-05-13 | -$1.55M derived: sum of 2 quarters · filed 2024-05-13 | $221.00K derived: sum of 3 quarters · filed 2024-05-13 | $947.00K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | -$955.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $818.00K derived: sum of 2 quarters · filed 2024-03-28 | $1.54M derived: sum of 3 quarters · filed 2024-03-28 | $247.00K 10-K · filed 2024-03-28 |
| 2022-09-30 | $1.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.50M derived: sum of 2 quarters · filed 2023-11-09 | $1.20M 10-Q · filed 2023-11-09 | $836.00K derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $726.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-14 | -$571.00K 10-Q · filed 2023-08-14 | -$937.00K derived: sum of 3 quarters · filed 2023-08-14 | -$60.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | -$1.30M 10-Q · filed 2023-05-12 | -$1.66M derived: sum of 2 quarters · filed 2023-05-12 | -$786.00K derived: sum of 3 quarters · filed 2023-05-12 | $145.00K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | -$366.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24 | $511.00K derived: sum of 2 quarters · filed 2023-03-24 | $1.44M derived: sum of 3 quarters · filed 2023-03-24 | $2.04M 10-K · filed 2023-03-24 |
| 2021-09-30 | $877.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $1.81M derived: sum of 2 quarters · filed 2022-11-10 | $2.40M 10-Q · filed 2022-11-10 | $963.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $931.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | $1.52M 10-Q · filed 2022-08-12 | $86.00K derived: sum of 3 quarters · filed 2022-08-12 | |
| 2021-03-31 | $593.00K 10-Q · filed 2022-05-13 | -$845.00K derived: sum of 2 quarters · filed 2022-05-13 | ||
| 2020-12-31 | -$1.44M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | -$1.41M 10-K · filed 2022-03-29 | ||
| 2020-09-30 | $30.00K 10-Q · filed 2021-11-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |